Odyssey Therapeutics Publishes Paper Titled 'TNFR2 agonism increases tissue and effector Treg cells In Journal Of Immunology
Benzinga Newsdesk 10 hours ago
News
Odyssey Therapeutics, Inc. (Nasdaq: ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and
Odyssey Therapeutics, Inc. (Nasdaq: ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced the publication of a research paper titled, "TNFR2 agonism increases tissue and effector Treg cells" in The Journal of Immunology. The manuscript was selected by the editors as a "Cutting Edge" article, highlighting the scientific significance of the findings.